Monument Capital Management Sells 239 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Monument Capital Management lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,956 shares of the medical research company’s stock after selling 239 shares during the period. Thermo Fisher Scientific makes up approximately 1.5% of Monument Capital Management’s investment portfolio, making the stock its 17th biggest holding. Monument Capital Management’s holdings in Thermo Fisher Scientific were worth $2,909,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in TMO. Winslow Evans & Crocker Inc. raised its stake in shares of Thermo Fisher Scientific by 3.7% during the fourth quarter. Winslow Evans & Crocker Inc. now owns 16,948 shares of the medical research company’s stock valued at $5,506,000 after acquiring an additional 610 shares in the last quarter. Legacy Capital Partners Inc. bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $211,000. Heritage Investors Management Corp raised its stake in shares of Thermo Fisher Scientific by 2.9% during the fourth quarter. Heritage Investors Management Corp now owns 36,894 shares of the medical research company’s stock valued at $11,986,000 after acquiring an additional 1,038 shares in the last quarter. Artemis Investment Management LLP raised its stake in shares of Thermo Fisher Scientific by 12.0% during the fourth quarter. Artemis Investment Management LLP now owns 95,072 shares of the medical research company’s stock valued at $30,843,000 after acquiring an additional 10,171 shares in the last quarter. Finally, Corbenic Partners LLC bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $31,000. 88.25% of the stock is owned by institutional investors and hedge funds.

Several analysts have recently weighed in on the stock. Evercore ISI raised shares of Thermo Fisher Scientific to an “outperform” rating in a research note on Thursday, November 14th. Cowen reaffirmed an “outperform” rating and set a $365.00 price target (up previously from $330.00) on shares of Thermo Fisher Scientific in a research note on Monday, January 6th. Stifel Nicolaus assumed coverage on shares of Thermo Fisher Scientific in a research note on Thursday, November 14th. They set a “buy” rating and a $345.00 price target for the company. Robert W. Baird lifted their price target on shares of Thermo Fisher Scientific from $305.00 to $319.00 and gave the company an “outperform” rating in a research note on Thursday, October 24th. Finally, Needham & Company LLC assumed coverage on shares of Thermo Fisher Scientific in a research note on Friday, January 3rd. They set a “strong-buy” rating and a $271.00 price target for the company. Two equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $323.27.

Shares of TMO traded up $0.78 during trading hours on Tuesday, reaching $332.80. 1,032,786 shares of the company traded hands, compared to its average volume of 999,018. The stock has a market capitalization of $131.82 billion, a P/E ratio of 29.93, a P/E/G ratio of 1.94 and a beta of 1.12. The company has a quick ratio of 1.23, a current ratio of 1.80 and a debt-to-equity ratio of 0.56. Thermo Fisher Scientific Inc. has a 12-month low of $233.71 and a 12-month high of $335.09. The business has a fifty day moving average price of $321.91 and a 200-day moving average price of $297.51.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $2.94 earnings per share for the quarter, beating analysts’ consensus estimates of $2.88 by $0.06. The firm had revenue of $6.27 billion for the quarter, compared to analyst estimates of $6.19 billion. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.16%. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period in the previous year, the company earned $2.62 earnings per share. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 12.33 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Tuesday, December 17th will be issued a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.23%. The ex-dividend date of this dividend is Monday, December 16th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 6.83%.

Thermo Fisher Scientific announced that its Board of Directors has authorized a share repurchase plan on Friday, November 8th that authorizes the company to buyback $2.50 million in outstanding shares. This buyback authorization authorizes the medical research company to purchase shares of its stock through open market purchases. Shares buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

In other news, CEO Marc N. Casper sold 47,729 shares of the business’s stock in a transaction on Friday, October 25th. The shares were sold at an average price of $295.88, for a total transaction of $14,122,056.52. Following the sale, the chief executive officer now directly owns 328,960 shares of the company’s stock, valued at $97,332,684.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.45% of the stock is owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Story: Limitations of the P/E Growth ratio

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.